U.S. drugmakers are increasingly licensing drug candidates from Chinese biotech firms, with 14 such deals worth up to $18.3 ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

A new drug is helping families who've spent years padlocking fridges, chaining garbage cans, and hiding food as their ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up to $812 million in a partnership deal aimed at developing drugs to treat cardiometabolic diseases, including obesity.

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game. The deal announced by Bristol ...

Bill Cassidy quietly explore a “most-favored nation” pricing policy for prescription drugs, and more. Health secretary Robert F. Kennedy Jr. yesterday appointed a new, smaller vaccine advisory ...